Pub Date : 2022-07-01DOI: 10.1097/BS9.0000000000000127
Mingzheng Hu, Yijie Wang, Jun Zhou
Defects in centrosomes are associated with a broad spectrum of hematological malignancies, such as leukemia and lymphoma. Centrosomes in these malignancies display both numerical and structural aberrations, including alterations in the number and size of centrioles, inappropriate post-translational modification of centrosomal proteins, and extra centrosome clustering. There is accumulating evidence that centrosome defects observed in hematological malignancies result from multiple factors, including dysregulation of the centrosome cycle and impairment of centriole biogenesis. In this review, we discuss the plausible mechanisms of centrosome defects and highlight their consequences in hematological malignancies. We also illustrate the latest therapeutic strategies against hematological malignancies by targeting centrosome anomalies.
{"title":"Centrosome Defects in Hematological Malignancies: Molecular Mechanisms and Therapeutic Insights.","authors":"Mingzheng Hu, Yijie Wang, Jun Zhou","doi":"10.1097/BS9.0000000000000127","DOIUrl":"https://doi.org/10.1097/BS9.0000000000000127","url":null,"abstract":"<p><p>Defects in centrosomes are associated with a broad spectrum of hematological malignancies, such as leukemia and lymphoma. Centrosomes in these malignancies display both numerical and structural aberrations, including alterations in the number and size of centrioles, inappropriate post-translational modification of centrosomal proteins, and extra centrosome clustering. There is accumulating evidence that centrosome defects observed in hematological malignancies result from multiple factors, including dysregulation of the centrosome cycle and impairment of centriole biogenesis. In this review, we discuss the plausible mechanisms of centrosome defects and highlight their consequences in hematological malignancies. We also illustrate the latest therapeutic strategies against hematological malignancies by targeting centrosome anomalies.</p>","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":"4 3","pages":"143-151"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/aa/7c/bs9-4-143.PMC9742116.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10712766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-01DOI: 10.1097/BS9.0000000000000119
Xi Zhang
Hematopoietic stem-cell transplantation (HSCT) is an important, potentially curative therapeutic option for hema-tological malignancies. However, poor and slow hematopoi- etic reconstitution remains a significant complication, which is correlated with abnormal hematopoietic stem-cell (HSC) func- tion. The maintenance and the preservation of HSC functional properties are supported by a highly specialized microenviron- ment within the bone marrow (BM), in which BM-derived mesenchymal stem cells (BMSCs) serve as the essential structural and functional basis for constituting the BM microenviron-ment. Damage, such as that due to chemotherapy, radiother- apy or inflammation, delays hematopoietic recovery or causes hematopoiesis dysfunction or failure, seriously affecting HSCT efficacy. 1 The key to remodeling and repairing the BM micro-environment lies in the repair of the niche structure by cellular therapies which include BMSCs. Research has increasingly confirmed that the most crucial functions of BMSCs are to main- tain the turnover of the BM stroma and skeletal tissues and to provide critical hematopoietic support. 2 However, the underly-ing mechanisms that regulate these different functions are not well known. In the recent BLOOD publication, the Dr. Zhao and Dr. Jiang group revealed that the retinoic acid-inducible gene I (RIG-I) plays a substantial role in regulating the stromal niche for hematopoietic reconstitution. 3 All-trans retinoic acid (ATRA) and inflammation stress upregulated RIG-I expres- sion, thus damaging the clonogenicity, the bone-forming ability of BMSCs and the supporting function in the stromal niche; mechanistically, this is achieved by suppressing the antioxidant impact of nuclear
{"title":"Beyond the horizon: the newly found sinner disturbing mesenchymal stromal niche.","authors":"Xi Zhang","doi":"10.1097/BS9.0000000000000119","DOIUrl":"https://doi.org/10.1097/BS9.0000000000000119","url":null,"abstract":"Hematopoietic stem-cell transplantation (HSCT) is an important, potentially curative therapeutic option for hema-tological malignancies. However, poor and slow hematopoi- etic reconstitution remains a significant complication, which is correlated with abnormal hematopoietic stem-cell (HSC) func- tion. The maintenance and the preservation of HSC functional properties are supported by a highly specialized microenviron- ment within the bone marrow (BM), in which BM-derived mesenchymal stem cells (BMSCs) serve as the essential structural and functional basis for constituting the BM microenviron-ment. Damage, such as that due to chemotherapy, radiother- apy or inflammation, delays hematopoietic recovery or causes hematopoiesis dysfunction or failure, seriously affecting HSCT efficacy. 1 The key to remodeling and repairing the BM micro-environment lies in the repair of the niche structure by cellular therapies which include BMSCs. Research has increasingly confirmed that the most crucial functions of BMSCs are to main- tain the turnover of the BM stroma and skeletal tissues and to provide critical hematopoietic support. 2 However, the underly-ing mechanisms that regulate these different functions are not well known. In the recent BLOOD publication, the Dr. Zhao and Dr. Jiang group revealed that the retinoic acid-inducible gene I (RIG-I) plays a substantial role in regulating the stromal niche for hematopoietic reconstitution. 3 All-trans retinoic acid (ATRA) and inflammation stress upregulated RIG-I expres- sion, thus damaging the clonogenicity, the bone-forming ability of BMSCs and the supporting function in the stromal niche; mechanistically, this is achieved by suppressing the antioxidant impact of nuclear","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":"4 3","pages":"179-180"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b9/9b/bs9-4-179.PMC9742105.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10731050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-01DOI: 10.1097/BS9.0000000000000131
Rong Yin, Yashu Li, Wen Tian, Fuling Zhou, Haojian Zhang
N6-Methyladenosine (m6A) is the most abundant modification in eukaryotic mRNA, and plays important biological functions via regulating RNA fate determination. Recent studies have shown that m6A modification plays a key role in hematologic malignancies, including acute myeloid leukemia. The current growth of epitranscriptomic research mainly benefits from technological progress in detecting RNA m6A modification in a transcriptome-wide manner. In this review, we first briefly summarize the latest advances in RNA m6A biology by focusing on writers, readers, and erasers of m6A modification, and describe the development of high-throughput methods for RNA m6A mapping. We further discuss the important roles of m6A modifiers in acute myeloid leukemia, and highlight the identification of potential inhibitors for AML treatment by targeting of m6A modifiers. Overall, this review provides a comprehensive summary of RNA m6A biology in acute myeloid leukemia.
{"title":"RNA m<sup>6</sup>A modification: Mapping methods, roles, and mechanisms in acute myeloid leukemia.","authors":"Rong Yin, Yashu Li, Wen Tian, Fuling Zhou, Haojian Zhang","doi":"10.1097/BS9.0000000000000131","DOIUrl":"https://doi.org/10.1097/BS9.0000000000000131","url":null,"abstract":"<p><p>N<sup>6</sup>-Methyladenosine (m<sup>6</sup>A) is the most abundant modification in eukaryotic mRNA, and plays important biological functions via regulating RNA fate determination. Recent studies have shown that m<sup>6</sup>A modification plays a key role in hematologic malignancies, including acute myeloid leukemia. The current growth of epitranscriptomic research mainly benefits from technological progress in detecting RNA m<sup>6</sup>A modification in a transcriptome-wide manner. In this review, we first briefly summarize the latest advances in RNA m<sup>6</sup>A biology by focusing on writers, readers, and erasers of m<sup>6</sup>A modification, and describe the development of high-throughput methods for RNA m<sup>6</sup>A mapping. We further discuss the important roles of m<sup>6</sup>A modifiers in acute myeloid leukemia, and highlight the identification of potential inhibitors for AML treatment by targeting of m<sup>6</sup>A modifiers. Overall, this review provides a comprehensive summary of RNA m<sup>6</sup>A biology in acute myeloid leukemia.</p>","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":"4 3","pages":"116-124"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742108/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10712764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-01DOI: 10.1097/BS9.0000000000000117
Dingrui Nie, Cunte Chen, Yangqiu Li, Chengwu Zeng
Regulated cell death (RCD) is essential for maintaining cell homeostasis and preventing diseases. Besides classical apoptosis, several novel nonapoptotic forms of RCD including NETosis, pyroptosis, ferroptosis, and cuproptosis have been reported and are increasingly being implicated in various cancers and inflammation. Disulfiram (DSF), an aldehyde dehydrogenase inhibitor, has been used clinically for decades as an anti-alcoholic drug. New studies have shown that DSF possesses potent anti-inflammatory and anti-cancer effects by regulating these new types of RCD. Here, we summarize the mechanisms and discuss the potential application of DSF in the treatment of cancers and inflammatory diseases.
{"title":"Disulfiram, an aldehyde dehydrogenase inhibitor, works as a potent drug against sepsis and cancer via NETosis, pyroptosis, apoptosis, ferroptosis, and cuproptosis.","authors":"Dingrui Nie, Cunte Chen, Yangqiu Li, Chengwu Zeng","doi":"10.1097/BS9.0000000000000117","DOIUrl":"https://doi.org/10.1097/BS9.0000000000000117","url":null,"abstract":"<p><p>Regulated cell death (RCD) is essential for maintaining cell homeostasis and preventing diseases. Besides classical apoptosis, several novel nonapoptotic forms of RCD including NETosis, pyroptosis, ferroptosis, and cuproptosis have been reported and are increasingly being implicated in various cancers and inflammation. Disulfiram (DSF), an aldehyde dehydrogenase inhibitor, has been used clinically for decades as an anti-alcoholic drug. New studies have shown that DSF possesses potent anti-inflammatory and anti-cancer effects by regulating these new types of RCD. Here, we summarize the mechanisms and discuss the potential application of DSF in the treatment of cancers and inflammatory diseases.</p>","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":"4 3","pages":"152-154"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742096/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10731048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-01DOI: 10.1097/BS9.0000000000000114
Qihua Zou, Shuyun Ma, Xiaopeng Tian, Qingqing Cai
Adult T-cell lymphoblastic lymphoma (T-LBL) is a rare and aggressive subtype of non-Hodgkin's lymphoma that differs from pediatric T-LBL and has a worse prognosis. Due to its rarity, little is known about the genetic and molecular characteristics, optimal treatment modalities, and prognostic factors of adult T-LBL. Therefore, we summarized the existing studies to comprehensively discuss the above issues in this review. Genetic mutations of NOTCH1/FBXW7, PTEN, RAS, and KMT2D, together with abnormal activation of signaling pathways, such as the JAK-STAT signaling pathway were described. We also discussed the therapeutic modalities. Once diagnosed, adult T-LBL patients should receive intensive or pediatric acute lymphoblastic leukemia regimen and central nervous system prophylaxis as soon as possible, and cranial radiation-free protocols are appropriate. Mediastinal radiotherapy improves clinical outcomes, but adverse events are of concern. Hematopoietic stem cell transplantation may be considered for adult T-LBL patients with high-risk factors or those with relapsed/refractory disease. Besides, several novel prognostic models have been constructed, such as the 5-miRNAs-based classifier, 11-gene-based classifier, and 4-CpG-based classifier, which have presented significant prognostic value in adult T-LBL.
{"title":"Comprehensive view on genetic features, therapeutic modalities and prognostic models in adult T-cell lymphoblastic lymphoma.","authors":"Qihua Zou, Shuyun Ma, Xiaopeng Tian, Qingqing Cai","doi":"10.1097/BS9.0000000000000114","DOIUrl":"https://doi.org/10.1097/BS9.0000000000000114","url":null,"abstract":"<p><p>Adult T-cell lymphoblastic lymphoma (T-LBL) is a rare and aggressive subtype of non-Hodgkin's lymphoma that differs from pediatric T-LBL and has a worse prognosis. Due to its rarity, little is known about the genetic and molecular characteristics, optimal treatment modalities, and prognostic factors of adult T-LBL. Therefore, we summarized the existing studies to comprehensively discuss the above issues in this review. Genetic mutations of <i>NOTCH1/FBXW7</i>, <i>PTEN</i>, <i>RAS</i>, and <i>KMT2D</i>, together with abnormal activation of signaling pathways, such as the JAK-STAT signaling pathway were described. We also discussed the therapeutic modalities. Once diagnosed, adult T-LBL patients should receive intensive or pediatric acute lymphoblastic leukemia regimen and central nervous system prophylaxis as soon as possible, and cranial radiation-free protocols are appropriate. Mediastinal radiotherapy improves clinical outcomes, but adverse events are of concern. Hematopoietic stem cell transplantation may be considered for adult T-LBL patients with high-risk factors or those with relapsed/refractory disease. Besides, several novel prognostic models have been constructed, such as the 5-miRNAs-based classifier, 11-gene-based classifier, and 4-CpG-based classifier, which have presented significant prognostic value in adult T-LBL.</p>","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":"4 3","pages":"155-160"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742094/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10712763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-01DOI: 10.1097/BS9.0000000000000123
Hui Wang, Wenchang Qian, Yingli Han, Pengxu Qian
The maintenance of the mammalian blood system depends on hematopoietic stem cells (HSCs), which are a rare class of adult stem cells with self-renewal and multilineage differentiation capacities. The homeostasis of hematopoietic stem cells is finely tuned by a variety of endogenous and exogenous regulatory factors, and disrupted balance will lead to hematological diseases including leukemia and anemia. Recently, emerging studies have illustrated the cellular and molecular mechanisms underlying the regulation of HSC homeostasis. Particularly, the rapid development of second-generation sequencing technologies has uncovered that many small noncoding RNAs (ncRNAs) are highly expressed in HSCs, including snoRNAs, miRNAs, tsRNAs, circular RNAs, etc. In this study, we will summarize the essential roles and regulatory mechanisms of these small ncRNAs in maintaining HSC homeostasis. Overall, this review provides up-to-date information in the regulation of HSC homeostasis by small ncRNAs, which sheds light into the development of therapeutic strategies against hematopoietic malignancies.
{"title":"Small noncoding RNAs play superior roles in maintaining hematopoietic stem cell homeostasis.","authors":"Hui Wang, Wenchang Qian, Yingli Han, Pengxu Qian","doi":"10.1097/BS9.0000000000000123","DOIUrl":"https://doi.org/10.1097/BS9.0000000000000123","url":null,"abstract":"<p><p>The maintenance of the mammalian blood system depends on hematopoietic stem cells (HSCs), which are a rare class of adult stem cells with self-renewal and multilineage differentiation capacities. The homeostasis of hematopoietic stem cells is finely tuned by a variety of endogenous and exogenous regulatory factors, and disrupted balance will lead to hematological diseases including leukemia and anemia. Recently, emerging studies have illustrated the cellular and molecular mechanisms underlying the regulation of HSC homeostasis. Particularly, the rapid development of second-generation sequencing technologies has uncovered that many small noncoding RNAs (ncRNAs) are highly expressed in HSCs, including snoRNAs, miRNAs, tsRNAs, circular RNAs, etc. In this study, we will summarize the essential roles and regulatory mechanisms of these small ncRNAs in maintaining HSC homeostasis. Overall, this review provides up-to-date information in the regulation of HSC homeostasis by small ncRNAs, which sheds light into the development of therapeutic strategies against hematopoietic malignancies.</p>","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":"4 3","pages":"125-132"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742093/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10712768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-05-17eCollection Date: 2022-04-01DOI: 10.1097/BS9.0000000000000106
Martina Cusan, Lili Wang
In human cancers, aberration of tumor suppressors and oncogenes cooperate to contribute to tumor initiation and progression.TP53, one of the best-known tumor suppressors, appears to have diverse roles through working together with different oncogenes. A good example is RAS mutations cooccurringwithTP53 lesions.KRAS hyper-activation leads to cell replicative senescence, which could be overcome by lesions in TP53, escaping immune clearance surveillance and promoting
{"title":"NEK2, a promising target in TP53 mutant cancer.","authors":"Martina Cusan, Lili Wang","doi":"10.1097/BS9.0000000000000106","DOIUrl":"https://doi.org/10.1097/BS9.0000000000000106","url":null,"abstract":"In human cancers, aberration of tumor suppressors and oncogenes cooperate to contribute to tumor initiation and progression.TP53, one of the best-known tumor suppressors, appears to have diverse roles through working together with different oncogenes. A good example is RAS mutations cooccurringwithTP53 lesions.KRAS hyper-activation leads to cell replicative senescence, which could be overcome by lesions in TP53, escaping immune clearance surveillance and promoting","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":" ","pages":"97-98"},"PeriodicalIF":0.0,"publicationDate":"2022-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/dd/41/bls-4-97.PMC9362867.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40715317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-05-17eCollection Date: 2022-04-01DOI: 10.1097/BS9.0000000000000107
Xiangrong Hu, Li Zhang, Qingsong Lin, Fengkui Zhang, Xin Zhao
Purpureocillium lilacinum (P lilacinum) is a rare pathogenic fungus, which mainly involves immunocompromised individuals. Here, we report a case of complicated multiple-organ infections involving skin, lungs, and spleen in a 63-year-old female with Evans' syndrome after 9 months of glucocorticoid treatment. Microbial examinations of skin biopsy and blood samples revealed P lilacinum infections. Posaconazole was effective in this patient. During anti-fungi treatment, she developed varicella-zoster virus infection and was diagnosed through next-generation sequencing examination. In conclusion, P lilacinum may affect different organ systems and is susceptible to posaconazole treatment. The molecular-based methods like microbial cell-free DNA sequencing could provide accurate and timely identification of a wide range of infections.
{"title":"Complicated multiple organ infection of <i>Purpureocillium lilacinum</i> and varicella-zoster virus infection in a patient with Evans' syndrome.","authors":"Xiangrong Hu, Li Zhang, Qingsong Lin, Fengkui Zhang, Xin Zhao","doi":"10.1097/BS9.0000000000000107","DOIUrl":"https://doi.org/10.1097/BS9.0000000000000107","url":null,"abstract":"<p><p><i>Purpureocillium lilacinum</i> (<i>P lilacinum)</i> is a rare pathogenic fungus, which mainly involves immunocompromised individuals. Here, we report a case of complicated multiple-organ infections involving skin, lungs, and spleen in a 63-year-old female with Evans' syndrome after 9 months of glucocorticoid treatment. Microbial examinations of skin biopsy and blood samples revealed <i>P lilacinum</i> infections. Posaconazole was effective in this patient. During anti-fungi treatment, she developed varicella-zoster virus infection and was diagnosed through next-generation sequencing examination. In conclusion, <i>P lilacinum</i> may affect different organ systems and is susceptible to posaconazole treatment. The molecular-based methods like microbial cell-free DNA sequencing could provide accurate and timely identification of a wide range of infections.</p>","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":" ","pages":"89-92"},"PeriodicalIF":0.0,"publicationDate":"2022-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ad/c4/bls-4-89.PMC9362862.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40715320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-05-17eCollection Date: 2022-04-01DOI: 10.1097/BS9.0000000000000108
Yuanyuan Luo, Chunya Ma, Yang Yu
Warfarin is a commonly used oral anticoagulant. Patients with artificial valve replacement, atrial fibrillation, pulmonary embolism, deep vein thrombosis, and other diseases require long-term anticoagulant oral treatment with warfarin. As warfarin exhibits prompt action with long maintenance time, it has become a key drug for the treatment of patients at risk of developing thrombosis or thromboembolism. Warfarin is a bican coumarin anticoagulant, that exhibits competitive action against vitamin K as its mechanism of action, thereby inhibiting the synthesis of coagulation factors-predominantly the vitamin K-dependent coagulation factors II, VII, IX, and X-in hepatocytes. Long-term warfarin is known to significantly increase the risk of organ bleeding in some patients, while some patients may need to reverse the anticoagulation effect. For instance, patients scheduled for emergency or invasive surgery may require rapid anticoagulation reversal. During such medical circumstances, fresh frozen plasma (FFP) is clinically used for the reversal of excess warfarin-associated anticoagulation, as it contains all the coagulation factors that can alleviate the abnormal blood anticoagulation status in such patients. Accordingly, this article aims to perform an in-depth review of relevant literature on the reversal of warfarin with FFP, and insightful deliberation of the application and efficacy of this clinical intervention.
{"title":"Application of fresh frozen plasma transfusion in the management of excessive warfarin-associated anticoagulation.","authors":"Yuanyuan Luo, Chunya Ma, Yang Yu","doi":"10.1097/BS9.0000000000000108","DOIUrl":"https://doi.org/10.1097/BS9.0000000000000108","url":null,"abstract":"<p><p>Warfarin is a commonly used oral anticoagulant. Patients with artificial valve replacement, atrial fibrillation, pulmonary embolism, deep vein thrombosis, and other diseases require long-term anticoagulant oral treatment with warfarin. As warfarin exhibits prompt action with long maintenance time, it has become a key drug for the treatment of patients at risk of developing thrombosis or thromboembolism. Warfarin is a bican coumarin anticoagulant, that exhibits competitive action against vitamin K as its mechanism of action, thereby inhibiting the synthesis of coagulation factors-predominantly the vitamin K-dependent coagulation factors II, VII, IX, and X-in hepatocytes. Long-term warfarin is known to significantly increase the risk of organ bleeding in some patients, while some patients may need to reverse the anticoagulation effect. For instance, patients scheduled for emergency or invasive surgery may require rapid anticoagulation reversal. During such medical circumstances, fresh frozen plasma (FFP) is clinically used for the reversal of excess warfarin-associated anticoagulation, as it contains all the coagulation factors that can alleviate the abnormal blood anticoagulation status in such patients. Accordingly, this article aims to perform an in-depth review of relevant literature on the reversal of warfarin with FFP, and insightful deliberation of the application and efficacy of this clinical intervention.</p>","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":" ","pages":"57-64"},"PeriodicalIF":0.0,"publicationDate":"2022-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/99/24/bls-4-57.PMC9362864.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40715318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}